Ketabon Showcases Innovative Ketamine Therapy Advances
Ketabon's Innovative Approach to At-Home Ketamine Therapy
Ketabon GmbH, a collaborative venture between HMNC Brain Health and Develco Pharma, is set to make waves at the upcoming European College of Neuropsychopharmacology Congress 2024. This event will take place in Milan, where the company will showcase groundbreaking advancements in ketamine therapy aimed at treating those with treatment-resistant depression (TRD).
Introducing KET01: A New Hope for Patients
Ketabon's primary focus will be on presenting KET01, an oral prolonged-release ketamine formulation. This innovative treatment addresses the needs of patients who have not found relief through traditional depression medications. The results from a Phase 2 trial of KET01 indicate significant improvements in depression severity with minimal side effects, reinforcing the potential of this new formulation.
Key Findings from Clinical Trials
The trial results showed that a daily dosage of 240mg of KET01 not only provides rapid alleviation of depressive symptoms but also boasts a favorable side effect profile compared to standard ketamine treatments. This is an encouraging development for individuals seeking alternative options for managing their depression.
Highlights from the ECNP 2024 Presentation
Executives from HMNC Brain Health and Develco Pharma, alongside researchers from the University Medical Center Hamburg-Eppendorf, will be presenting two significant posters during the congress. These presentations will concentrate on the tolerability of KET01 and its impact on sleep quality, a common concern associated with existing ketamine therapies.
Session Information
Two exciting sessions planned include:
- Session title: PS01
Poster presentation number: P1090
Title: Acute Tolerability of Antidepressant Dose of Oral Prolonged-Release Ketamine (KET01)
Presenter: A. Damyanova and team
Track: Mental Conditions
Date & Time: Sunday, September 22, 2024, from 12:35 to 14:00 CET - Session title: PS01
Poster presentation number: P1084
Title: Evaluation of Sleep Quality During Treatment with KET01
Presenter: E. Papanastasiou and team
Track: Mental Conditions
Date & Time: Sunday, September 22, 2024, from 12:35 to 14:00 CET
KET01: A User-Friendly Treatment Option
Dr. Hans Eriksson, Chief Medical Officer of Ketabon, underscores the significance of these findings, stating that KET01 allows for treatment without significant sleep disturbances or sedation, which are typical drawbacks of other ketamine formulations. The oral administration of KET01 offers a unique opportunity for patients to manage their treatment from the comfort of their own homes, thereby enhancing the quality of life without significantly impacting daily routines.
The Future of Ketabon and Mental Health Treatments
The Ketabon initiative continues to expand its horizons, with the potential expansion of the oral prolonged-release ketamine formulation into additional therapeutic areas beyond depression, such as anxiety, aggression, PTSD, and panic disorders. This potential broadening of applications could significantly enhance the treatment landscape and offer new options for patients struggling with these conditions.
About Ketabon GmbH and Its Partners
As a joint venture, Ketabon embodies the innovative spirit of HMNC Brain Health and Develco Pharma, focusing on developing effective mental health treatments. HMNC Brain Health is renowned for its personalized therapy approaches and pioneering precision psychiatry, while Develco Pharma specializes in advanced oral drug formulations. Together, they aim to redefine care modalities for mental health.
Frequently Asked Questions
What is KET01?
KET01 is an oral prolonged-release ketamine formulation intended for the treatment of treatment-resistant depression.
When will Ketabon present its findings?
Ketabon will present its findings at the ECNP Congress on September 22, 2024.
What are the outcomes of KET01's Phase 2 trial?
The Phase 2 trial demonstrated rapid improvements in depression severity with a favorable side effect profile.
How does KET01 compare to traditional ketamine treatments?
KET01 is designed to minimize side effects such as sleep disturbances and sedation common with traditional forms of ketamine therapy.
What is the mission of Ketabon?
Ketabon aims to develop effective at-home treatments for mental health conditions, enhancing patient quality of life.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.